The effects of gliclazide and other sulfonylureas on low-density lipoprotein oxidation in vitro

Metabolism: Clinical and Experimental

Volumn 46, Issue SUPPL.1, 1997, Pages 22-25

  O'Brien, Richard C ^a,b   Luo, Ming ^a  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; ASCORBIC ACID; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; LOW DENSITY LIPOPROTEIN; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; LIPID OXIDATION; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SCAVENGING SYSTEM;

ADMINISTRATION, ORAL; ADULT; ANTIOXIDANTS; ASCORBIC ACID; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; GLICLAZIDE; GLIPIZIDE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; SULFONYLUREA COMPOUNDS; TOLBUTAMIDE;

EID: 0031429538     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(97)90312-7     Document Type: Article

References (23)

1. Donahue RP, Orchard TJ: Diabetes mellitus and macrovascular complications. Diabetes Care 15:1141-1155, 1992
2. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: The Framingham Study. Diabetes Care 2:120-126, 1979
3. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412, 1991
4. Mullarkey CJ, Edelstein D, Brownlee M: Free radical generation by early glycation products: A mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173:932-939, 1990
5. Hicks M, Delbridge L, Yue DK, et al: Catalysis of lipid peroxidation by glucose and glycosylated collagen. Biochem Biophys Res Commun 151:649-655, 1988
6. Barnett PA, Gonzalez RG, Chylack LT, et al: The effect of oxidation on sorbitol pathway kinetics. Diabetes 35:426-432, 1986
7. Karpen CW, Cataland S, O'Dorisio TM, et al: Production of 12 HETE and vitamin E status in platelets from type 1 human diabetic subjects. Diabetes 34:526-531, 1985
8. Yue DK, McLennan S, McGill M, et al: Abnormalities of ascorbic acid metabolism and diabetic control: Differences between diabetic patients and diabetic rats. Diabetes Res Clin Pract 9:239-244, 1990
9. Scott NA, Jennings PE, Brown J, et al: Gliclazide: A general free radical scavenger. Eur J Pharmacol 208:175-177, 1991
10. Jennings PE, Scott NA, Saniabadi AR, et al: Effects of gliclazide on platelet reactivity and free radicals in type II diabetic patients: Clinical assessment. Metabolism 41:36-39, 1992
11. Florkowski CM, Richardson MR, Leugen C, et al: Effects of gliclazide on thromboxane B2, parameters of haemostasis, fluorescent IgG, and lipid peroxides in non-insulin dependent diabetes mellitus. Diabetes Res 9:87-90, 1988
12. Steinberg D, Parthasarathy S, Carew TE, et al: Beyond cholesterol: Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320:915-924, 1989
13. Esterbauer H, Striegl G, Puhl H, et al: Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 570:254-267, 1989
14. McDowell IFW, McEneny J, Trimble ER: A rapid method for measurement of the susceptibility to oxidation of low-density lipoprotein. Ann Clin Biochem 32:167-174, 1995
15. Regnstrom J, Nilsson J, Tornvall P, et al: Susceptibility to low density lipoprotein oxidation and coronary atherosclerosis in man. Lancet 339:1183-1186, 1992
16. National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-1057, 1979
17. Holmes B, Heel RC, Brogden RN, et al: Gliclazide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy in diabetes mellitus. Drugs 27:301-327, 1984
18. McEvoy GK (ed): American Hospital Formulary Service (AHFS 95) (ed 37). Bethesda, MD, American Society of Health-System Pharmacists, 1995
19. Ferner RE, Chaplin S: The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokinet 12:379-401, 1987
20. Jennings PE, Chirico S, Jones AF, et al: Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 6:151-154, 1987
21. Esterbauer H, Rotheneder M, Striegl G, et al: Vitamin E and other lipophilic antioxidants protect LDL against oxidation. Fat Sci Technol 91:316-324, 1989
22. Tsai EC, Hirsch IB, Brunzell JD, et al: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43:1010-1014, 1984
23. Jennings PE: From hemobiology to vascular disease: A review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease. J Diabetes Complications 8:226-230, 1994